港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

485.171

+2.8150.58%

漲家數：21

跌家數：10

平家數：2

市盈率：- -

高：489.931

開：482.072

低：481.405

收：482.357

成交量：6,161.09萬

成交額：12.82億

市值：3,079.80億

流通市值：2,738.27億

資料載入中...

總覽新聞資訊

港股異動 | 劑泰科技-P(07666)早盤升逾15% 領升港股AI製藥板塊 AI4S商業化加速落地

禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數

亞馬遜擴大 AI 機櫃拉貨，世芯、緯穎、鴻海出貨強勁

基石藥業-B(02616.HK)獲納入港股通標的證券名單

基石藥業-B(02616.HK)：公司獲納入港股通

和鉑醫藥-B(02142)：公司股份獲納入滬港通及深港通的股份名單

高盛、傑富瑞齊聲看好基石藥業-B(02616.HK)：CS2009療效信號持續增強關鍵催化劑有望密集兑現

開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)

康方雙抗再贏K藥！港股通創新藥熱度飆升

康諾亞-B(02162)：王閩川辭任非執行董事

康諾亞-B(02162.HK)：王閩川辭任非執行董事

百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

澤璟製藥(688266.SH)：注射用人促甲狀腺素β新適應症上市申請獲得受理

國內首款AI輔助創新藥獲批上市！西湖大學聯合研發僅用時三年半

迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心

每日经济新闻

創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度

創新藥投資，優先佈局這些可把握的機會

证券市场周刊

復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=15"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":485.17123,"timestamp":1789632487194,"preClose":482.35672,"halted":0,"volume":61610930,"delay":0,"changeRate":0.005835,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":2.814514,"latestTime":"09-17 16:00:00","open":482.07187,"high":489.93134,"low":481.40475,"amount":1281540013.5,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.002293,"increases":18,"decrements":10,"flats":4,"marketCap":307980316848,"floatMarketCap":273827471128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":485.17123,"volume":61610930,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.002293,"peRate":160.310337,"marketCap":307980316848,"floatMarketCap":273827471128,"timestamp":1789632487194,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":10,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:15,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665539313","title":"港股異動 | 劑泰科技-P(07666)早盤升逾15% 領升港股AI製藥板塊 AI4S商業化加速落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665539313","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665539313?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:43","pubTimestamp":1788745407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P早盘涨超15%，领涨AI制药概念股。截至发稿，涨12.81%，报15.59港元，成交额1.1亿港元。消息面上，上交所9月4日盘后发布通知，剂泰科技-P正式调入港股通标的证券名单，该调整将于9月7日(周一)起生效。这意味着内地投资者自此可通过沪深港通直接买卖剂泰科技，正式解锁南向资金。值得注意的是，上半年，剂泰科技NanoForge商业化成果进入集中释放期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","VTHR","BK1574","VXUS","AGIX","ARTY","07666","QTOC","BK4588","BK4585","AIPO","KCAI","01477","CHAT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665398982?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","09637","BK1191","BK1574","HSCI","159938","FLHK","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665981693","title":"亞馬遜擴大 AI 機櫃拉貨，世芯、緯穎、鴻海出貨強勁","url":"https://stock-news.laohu8.com/highlight/detail?id=2665981693","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665981693?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:45","pubTimestamp":1788741906,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，供应链传出，北美云端服务供应商龙头亚马逊旗下 AWS 近期扩大 AI 服务器机柜拉货，台积电、世芯-KY、纬颖、鸿海等协力厂出货动能强劲。亚马逊日前再次上修今年资本支出，从原估计 2,000 亿美元提升至 2,200 亿美元，主要用于 AI 基础建设，包括资料中心、服务器、网路设备等需求。亚马逊执行长贾西看好 AI 算力供不应求态势延续到 2027 年，甚至已看见 2028 年强劲需求。AWS 的 AI 业务与自研芯片规模已成长至 250 亿美元，维持三位数百分比成长。Annapurna Labs 客制化 ASIC 芯片大多交由台积电以 3 奈米先进制程生产。世芯是 AWS 自研 AI 芯片重要伙伴，看好本季单季营收与获利将创新高，第 4 季持续看增，3 奈米 AI 加速器需求优于先前评估，年底前可设计定案。AWS 的 ASIC AI 机柜由纬颖负责组装并供应交换机托盘，鸿海切入 CPU 托盘。鸿海轮值 CEO 蒋集恒表示，今年 ASIC 专案取得新进展，将 ASIC 服务器市占率目标设定在 40% 以上。 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2287940","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU2168564149.EUR","LU0965509283.SGD","LU0788109477.HKD","AVEM","LU1066051811.HKD","LU0572940350.SGD","LU2242649171.HKD","HK0000914660.USD","LU2452424414.USD","BK4592","AZYY","LU0312595415.SGD","LU0882747503.HKD","IE0009G5SDU7.USD","IE00B3M56506.USD","LU2065170008.USD","LU2250418816.HKD","FDTX","LU2505996681.GBP","RTH","LU1935042991.SGD","LU1778281490.HKD","LU1712237335.SGD","LU0390134368.USD","SG9999014914.USD","IE000M9KFDE8.USD","LU1852331112.SGD","SG9999004303.SGD","LU0215105999.USD","LU1629891620.HKD","LU2592432038.USD","CGDG","IE0004445239.USD","LU0820561909.HKD","LU2746668461.USD","LU0384037296.USD","IE00BZ199S13.USD","LU2430703251.USD","IE00BZ1G4Q59.USD","LU2237438978.USD","TSMU","AMZY","IE0004091025.USD","LU2750360997.AUD","LU0310800379.SGD","LU1989772840.SGD","LU0359202008.SGD","LU0417517546.SGD","LU2764263039.SGD","TSMX","LU1267930490.SGD","SPWO","LU1935043023.USD","LU1815333072.USD","LU2211815571.USD","LU0345768153.USD","AIQ","LU2552382132.HKD","BAI","IE00B5TLWC47.USD","LU0267386448.USD","SGXZ44715902.SGD","IE00BJJMRY28.SGD","BK4534","LU2317271919.USD","LU2065171311.SGD","SG9999017495.SGD","LU0061475181.USD","USAW.SI","LU1023057109.AUD","LU2360108059.USD","LU1153585028.USD","BK4503","LU1244550577.SGD","LU0029864427.USD","LU1718418525.SGD","CORO","IE00BMPRXR70.SGD","LU2264538146.SGD","LU2089283258.USD","BK4527","BK1167","LU1280957306.USD","IE00BQXX3C00.GBP","LU1935043536.SGD","LU0359201612.USD","LU0889565833.HKD","LU0345770308.USD","IE00B775H168.HKD","LU0640476718.USD","LU2054465674.USD","LU0823421333.USD","ONLN","STSM","HULL","SG9999018865.SGD","LU2756315318.SGD","IE000MB6IJN5.SGD","IE00B19Z3B42.SGD","LU0072462426.USD","LU0541502299.USD","LU1429558221.USD","LU2063271972.USD","LU0719512351.SGD","IE00B3S45H60.SGD","LU1435385759.SGD","BK4612","IE00B1BXHZ80.USD","LU0320765489.SGD","LU0466842654.USD","SG9999004220.SGD","LU0683600562.USD","IE00BYQQ9H92.USD","AMZN","SGXZ51526630.SGD","BK1504","LU0345774391.USD","LU2552382058.USD","IE00BKDWB100.SGD","AMZZ","LU0130103400.USD","LU0203202063.USD","LU0742534661.SGD","LU2487616109.SGD","IE00B19Z9505.USD","LU0211328371.USD","LU0314104364.USD","LU0964807845.USD","LU0070217475.USD","LU2361045086.USD","SG9999014906.USD","LU0072461881.USD","SG9999015986.USD","LU1861559042.SGD","LU0308772762.SGD","LU1508157978.USD","LU1839511570.USD","LU2083900584.USD","LU0792757196.USD","LU2491050071.SGD","LU0265550359.USD","IE00BD6J9T35.USD","LU0097036916.USD","CHPX","LU1691799644.USD","BK4550","IE00BMPRXN33.USD","LU0823434740.USD","IE00BJTD4N35.SGD","LU0107464264.USD","LU1116320901.HKD","LU2237443978.SGD","LU1674673691.USD","LU1201861165.SGD","LU0251131958.USD","LU0162691827.USD","BK4591","LU0109391861.USD","EMC","LU0124676726.USD","03145","LU0354030438.USD","LU0354030511.USD","LU2552382215.SGD","LU1868837300.USD","LU0642271901.SGD","LU0289960550.SGD","LU2108987350.USD","LU2092627202.USD","LU0256863811.USD","LU0345774631.USD","LU2860962120.EUR","LU2430703095.HKD","TSMY","TINS","LU0127658192.USD","WUGI","LU1868837722.USD","LU0130102774.USD","LU2294711713.HKD","LU1868836914.USD","AVSE","ADVE","BK1508","LU1201861249.SGD","LU2381873111.SGD","LU0541501648.USD","LU2111349929.HKD","AMZU","BK4605","LU2896262040.SGD","BK4543","TSMZ","LU0345769631.USD","LU2458330243.SGD","IE00BK4W5M84.HKD","LU2023251221.USD","LU0048584097.USD","LU1267930573.SGD","IE00B4JS1V06.HKD","LU2168564222.USD","IE000WAW04H5.SGD","LU0289941410.SGD","LU2756315664.SGD","IE00B3SWFQ91.USD","LU1066051498.USD","SG9999015978.USD","IE0005OL40V9.USD","LU0154236417.USD","LU2242650005.HKD","LU0061474705.USD","LU1917777945.USD","LU1623119135.USD","LU2420271590.USD","IE000KEQY171.SGD","LU0256863902.USD","LU0070302665.USD","LU0708995401.HKD","LU1935042488.USD","LU0359201885.HKD","LU1934455194.USD","BK1574","LU0251132253.USD","LU2236285917.USD","BK4512","LU1935043452.HKD","IE0004086264.USD","IE00B19Z8X17.USD","BK4596","LU0787776722.HKD","IE0001KFT4U8.USD","LU2750360641.GBP","EMM","LU0143551892.USD","IE000F7OJYX1.SGD","LU0348723411.USD","LU1791710400.SGD","CGGO","LU2211814178.USD","LU1211504680.USD","IE00BMPRXQ63.HKD","HK0000914686.HKD","LU0238689110.USD","AMZD","LU2168564065.EUR","LU0048573561.USD","LU0096362180.USD","IE000SO60NU8.SGD","LU0980610538.SGD","LU0965509101.SGD","LU1868837565.USD","AMZP","LU0234572021.USD","SGXZ81514606.USD","LU1674673428.USD","LU2506951792.HKD","LU0316494557.USD","LU2471134952.CNY","LU1880398554.USD","LU2357305700.SGD","LU1366192091.USD","IE00BJJMRX11.SGD","LU2249611893.SGD","LU1037948897.HKD","LU2092937148.SGD","BK4559","LU0572939691.SGD","LU0096364046.USD","LU0198837287.USD","LU0456855351.SGD","LU0061474960.USD","IE00B7SZLL34.SGD","LU2077746001.SGD","IE00B775SV38.USD","CLIX","IE00BQXX3F31.USD","LU0949170426.SGD","LU1267930730.SGD","LU0170899867.USD","IE00BKVL7J92.USD","BK4561","BK4554","LU2265009873.SGD","SGXZ31699556.SGD","LU0965509010.AUD","LU0077335932.USD","LU0082616367.USD","LU2087625088.SGD","LU0323591593.USD","IE000YTNTUN2.SGD","LU1244550494.USD","LU0878004406.USD","LU0823414551.USD","LU2361044865.SGD","SGXZ80539844.SGD","LU1066053197.SGD","IE00B1XK9C88.USD","LU2764263203.CNY","LU2168564495.EUR","IE00BFSS8Q28.SGD","LU1868838027.USD","SG9999015952.SGD","LU0943347566.SGD","LU0786609619.USD","LU0648001328.SGD","LU0234570918.USD","SG9999000418.SGD","CNEQ","LU1791710582.SGD","LU0823421416.USD","TSM","LU2362540622.SGD","LU2462591350.SGD","LU0265550946.USD","LU1119994496.HKD","LU2023250843.SGD","SG9999018857.SGD","LU0158827948.USD","AMZO","LU0175139822.USD","IE000BZT7R73.USD","LU1244550221.USD","BK4598","TEK","HK0000304797.USD","LU0689472784.USD","ILDR","LU2461242641.AUD","AMZG","LU1282649067.USD","LU1046421795.USD","LU0174119429.USD","LU2746668974.SGD","LU1861127337.USD","LU1868836757.USD","LU2211817866.USD","02038","LU0053666078.USD","LU1861558580.USD","LU1868837136.USD","LU0878005551.USD","LU1934455863.HKD","LU1127390331.HKD","LU2213496289.HKD","LU2028103732.USD","BK4602","LU2237443622.USD","LU1633808545.USD","LU2247934214.USD","BK4220","LU2023250504.SGD","LU1069344957.HKD","LU0210528500.USD","LU2106854487.HKD","LU2357125470.USD","BK4533","LU0345769128.USD","BK4548","LU2092937221.SGD","BK1100","BK4524","LU2298321311.HKD","LU2471134879.HKD","LU2097829019.USD","CGNG","OGIG","LU2360032135.SGD","SAMZNmain","LU0648000940.SGD","KNOW","LU2999663052.SGD","LU1035775433.USD","IE000ITXATA3.USD","BLOX","LU0488056044.USD","LU0784385170.HKD","LU2602419157.SGD","LU0210536198.USD","TWSC","LU1084165304.USD","BK4581","LU2403377893.USD","LU1074936037.SGD","LU2133065610.SGD","LU0820561818.USD","LU1720051108.HKD","SPTE","IE00BFSS7M15.SGD","LU2125154778.USD","LU0276348264.USD","TTEQ","LU0708994859.HKD","IE000W1ABFV2.USD","LU0210533765.USD","LU0871640123.AUD","LU0823414478.USD","LU0985320562.USD","LU0157215616.USD","AMZW","LU1988902786.USD","BK4579","LU1323610961.USD","HK0000532082.HKD","BK4505","LU0251142724.SGD","LU0724617625.USD","LU2491049909.HKD","TSMG","IE00B19Z3581.USD","ESIM","LU2237443382.USD","LU0208291251.USD","BK1587","IE0004445015.USD","LU0784384876.USD","LU1496350502.SGD","LU2637965513.SGD","IE0002270589.USD","LU2430703178.SGD","LU2456880835.USD","LU0143863198.USD","SGXZ99366536.SGD","LU1048588211.SGD","BK4538","IE00BJLML261.HKD","LU1064131342.USD","LU0072462343.USD","LU2462591277.SGD","BK4535","LU2462157665.USD","LU0494093205.USD","SG9999001077.SGD","LU1814569148.SGD","LU0138981039.USD","SMH","LU0203201768.USD","LU0302445910.USD","LU0094547139.USD","LU1037948541.HKD","LU2065171402.SGD","LU0080751232.USD","LU1235294995.USD","SG9999002224.SGD","BK4551","LU2275660780.HKD","LU2065169927.USD","LU0957791311.USD","LU0672654240.SGD","LU1496350171.SGD","LU2463028550.USD","BK4532","LU0820562030.AUD","CGIC","LU0882574139.USD","LU1935042215.USD","BK4566","LU1316542783.SGD","BK4141","BK4588","LU2471134523.USD","LU2087621335.USD","LU2023250330.USD","LU2491050154.USD","LU0345768740.USD","IE0009356076.USD","LU1979441026.SGD","IE00BQXX3D17.EUR","LU2089284900.SGD","LU1145028129.USD","IE00BK4W5L77.USD","LU0320765059.SGD","IE0000B7K699.USD","LU0345770993.USD","LU0823434583.USD","LU2471134796.USD","LU0310799852.SGD","LU1066051225.USD","LU1804176565.USD","LU0011850046.USD","LU2362541273.HKD","SGXZ23171101.USD","LU0143863784.USD","SG9999014880.SGD","LU0353189763.USD","LU2168563687.JPY","LU0784385840.USD","LU1880398471.USD","LU2663582299.SGD","LU2362541513.USD","LU2543165471.USD","LU1366333091.USD","LU2041044095.USD","LU2764262908.HKD","IE00B7KXQ091.USD","LU1301847155.USD","BK4122","LU0109392836.USD","LU0861579265.USD","LU2361044949.HKD","LU2125154935.USD","IE00BWXC8680.SGD","HK0000304805.HKD","LU1261432733.SGD","LU0079474960.USD","LU0353189680.USD","LU0264606111.USD","LU1551013342.USD","SG9999015945.SGD","AMAA","LU1116320737.USD","LU1914381329.SGD","UMMA","LU0158827781.USD","LU1934455277.USD","LU0133085943.USD","FXCNY","LU1282649810.SGD","LU1823568750.SGD","IE00BJTD4V19.USD","IE00B5949003.HKD","LU1989772923.USD","LU2505996509.AUD","LU0342679015.USD","LU0128525929.USD","IE0034235303.USD","LU2237957811.SGD","SG9999014898.SGD","LU0784383803.USD","ASIA","LU2720916845.USD","LU0889566641.SGD","GB00BDT5M118.USD","LU0149725797.USD","LU0528227936.USD","LU1548497426.USD","CWI","LU0056508442.USD","LU0823411888.USD","LU2458330169.SGD","BK4604","LU1803068979.SGD","LU0965508806.USD","LU1232071149.USD","IE00B4YYXB79.USD","BK4585","LU0689626769.HKD","LU1974910355.USD","LU1989764664.SGD","LU1868836591.USD","LU2360106780.USD","IE00BKPKM429.USD","LU2237443549.SGD","LU1989764748.USD","LU2326559502.SGD","06669","IE0003U64NQ7.SGD","LU0211327993.USD","BK4526","AVXC","LU1551013425.SGD","LU2271345857.HKD","LU2237957902.USD","IE00B19Z8W00.USD","LU2417539215.USD","MEMX","LU2954938101.SGD","SG9999002232.USD","LU1267930813.SGD","WANT","IE00BN29S564.USD","BK4507","IE00BHPRN162.USD","IE00BFXG0V08.USD","LU1883839398.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398386","title":"基石藥業-B(02616.HK)獲納入港股通標的證券名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665398386?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:32","pubTimestamp":1788741157,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665338398","title":"基石藥業-B(02616.HK)：公司獲納入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2665338398","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665338398?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:27","pubTimestamp":1788740821,"startTime":"0","endTime":"0","summary":"格隆汇9月7日丨基石药业-B(02616.HK)发布公告，公司发行并于香港联交所上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。\r\n\r\n　　基石药业首席执行官、研发总裁及执行董事杨建新博士表示：“本次成功获纳入港股通标的证券名单，充分彰显了资本市场对本公司创新实力与长期发展潜力的高度认可。本次纳入有望进一步丰富本公司投资者结构，提升本公司股票在二级市场的流动性。展望未来，基石药业将持续推动核心资产的全球开发，凭借高效的管线推进与商业化布局，夯实核心竞争力，为广大投资者创造长期、可持续的价值回报。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260907/32361373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02616","FLHK","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665602733","title":"和鉑醫藥-B(02142)：公司股份獲納入滬港通及深港通的股份名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2665602733","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665602733?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:17","pubTimestamp":1788740238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，自2026年9月7日起，本公司股份获纳入沪港通及深港通的股份名单，中国内地的合资格投资者可透过沪港通及深港通计划直接投资股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665360401","title":"高盛、傑富瑞齊聲看好基石藥業-B(02616.HK)：CS2009療效信號持續增強 關鍵催化劑有望密集兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665360401","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665360401?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:02","pubTimestamp":1788739364,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601053","title":"開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:01","pubTimestamp":1788739288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","APXH","09939","XLVI","PBPH","BMED","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1617","BK1191","IBBQ","BK1161","AGIX","02196","LNGR","ARTY","06978","AIPO","CHAT","BK1141","VTHR","BK4585","BK1515","QTOC","03696","KCAI","BK4588","VXUS","MEDX","BK1593","02228","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364125","title":"康方雙抗再贏K藥！港股通創新藥熱度飆升","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364125","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364125?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 19:16","pubTimestamp":1788693360,"startTime":"0","endTime":"0","summary":"港股通创新药终于动起来了，9月4日，板块放量三连涨，100%创新药研发标的——港股通创新药ETF华宝成功收复年线外的所有均线。港股通创新药板块受何驱动，新一轮行情开始启动了？以100%布局创新药的港股通创新药ETF华宝为例，其覆盖的48家创新药研发类公司中，31家上半年实现盈利，其中6家同比扭亏为盈，归母净利同比正增长的多达33家，占比近七成。文中提及个股在恒生港股通创新药精选指数中的权重占比情况见配图。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-06/doc-iniqwwys9986173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0417516902.SGD","LU1720050803.USD","LU0634319403.HKD","LU2476274720.SGD","LU0540923850.HKD","LU0348825331.USD","LU1961090484.USD","LU0348784397.USD","LU2778985437.USD","LU0348767384.USD","LU0348735423.USD","520880","LU0348827113.USD","LU0561508036.HKD","IE00BPRC5H50.USD","09926","LU0348783233.USD","LU2399975544.HKD","LU1794554557.SGD","LU0417516571.SGD","LU2488822045.USD","BK1161","LU2476274308.USD","IE00B543WZ88.USD","BK1574","LU0348766576.USD","KURE","LU0417516738.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665646113","title":"康諾亞-B(02162)：王閩川辭任非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665646113","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665646113?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布公告，王闽川博士已递交辞呈，辞去公司非执行董事职务，自2026年9月4日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02162","BK1161","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364619","title":"康諾亞-B(02162.HK)：王閩川辭任非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364619?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02162","BK1583","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665709364","title":"百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665709364","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665709364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:31","pubTimestamp":1788690660,"startTime":"0","endTime":"0","summary":"证券日报网讯9月6日，百利天恒发布公告称，公司计划于2026年9月16日15：00-17：00参加科创板2026年半年度创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","BK0239","LNGR","91194","BK1574","IBBQ","159992","BK1161","06978","MEDX","KSTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361627","title":"澤璟製藥(688266.SH)：注射用人促甲狀腺素β新適應症上市申請獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361627","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361627?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:36","pubTimestamp":1788680173,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，公司递交的注射用人促甲状腺素β(曾用名：注射用重组人促甲状腺激素，商标：泽速宁®)新适应症上市申请获得受理，本次获得受理的适应症是用于无远处转移的分化型甲状腺癌患者甲状腺全切或近全切除术后协同放射性碘(131I)清除残余甲状腺组织的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","688266","BK1191","BK1574","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665403361","title":"國內首款AI輔助創新藥獲批上市！西湖大學聯合研發 僅用時三年半","url":"https://stock-news.laohu8.com/highlight/detail?id=2665403361","media":"快科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665403361?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:30","pubTimestamp":1788679839,"startTime":"0","endTime":"0","summary":"快科技9月6日消息，据西湖大学微信公众号消息，近期，由西湖大学、西湖实验室、西湖制药联合研发的创新药——盐酸伊司特韦片 正式获得国家药品监督管理局附条件批准上市。据悉，它是国内首款凭借AI辅助研发而获批上市的原创药——从源头发现到完成临床试验，仅用时三年半。这也是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8wCSabf9QIo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["ARTY","MEDX","IPOS","VTHR","AIPO","BK1161","06978","LNGR","CHAT","159992","IBBQ","QTOC","BK1574","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361549","title":"迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361549","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361549?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 14:57","pubTimestamp":1788677820,"startTime":"0","endTime":"0","summary":"迪哲医药对每经记者表示，公司始终认为，上市公司股价的长期走势根本上取决于基本面和经营实绩，并对长期发展充满信心。2026年8月至今，迪哲医药自愿披露多份利好公告。2026年9月3日盘后，迪哲医药发布了关于董事、高级管理人员减持股份计划公告。在发布高管减持计划后的首个交易日，迪哲医药股价表现不佳，盘中跌幅一度超过6%，收盘下跌5.01%。截至9月4日，迪哲医药收盘价报57.01元，市值约为265.5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","MEDX","WX","BK4550","159992","06978","FDN","BK4585","BK1161","CXO","IBBQ","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665538368","title":"創新藥投資，優先佈局這些可把握的機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665538368","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665538368?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:51","pubTimestamp":1788591110,"startTime":"0","endTime":"0","summary":"当AI行情阶段性休整、市场四处寻找下一条主线之时，创新药板块悄然走出一轮反弹行情。Wind数据显示，2026年6月9日至9月2日，恒生沪深港创新药50指数涨幅达到33.08%，CXO指数涨幅46.07%。但赛道本身波动性也极强。2025年前三季度，部分创新药指数最高涨幅超100%，随后自去年10月开启长达8个月的深度调整，截至2026年5月底，板块最大回撤超过30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866007987.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866007987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","06978","BK1574","LNGR","MEDX","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665936888?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VTHR","MRNX","BBP","HK0000320223.HKD","QTOC","HK0000306685.HKD","HK0000306701.USD","01477","BK1191","CHAT","AGIX","03069","HK0000165453.HKD","HK0000320264.USD","BK1574","AIPO","BK1161","IBBQ","02696","MRNY","ARTY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":15,"totalSize":329,"code":"91000000","status":"200"}]}}